ZoomNMR Zooming in on small-molecule ligands by magnetic resonance
- Coordinator
- Ludwig-Maximilians-Universitaet Muenchen, Germany
- Runs
- 1 September 2025 to 30 April 2031
- Status
- Running
- EU funding
- €2.0m
- Total cost
- €2.0m
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101170460
What the project is doing
In the project's own words, from its summary on CORDIS.
Small molecules are critical players in the chemistry of life. In the role of substrates, cofactors, solvent, inhibitors or activators, they steer the activities of proteins and nucleic acids. For mechanistic studies, it would be desirable to single out a small ligand from a large macromolecular complex, even if their sizes lie several orders of magnitude apart, and follow its fate during chemical and structural transformations.
Few experimental techniques would achieve this under native conditions. NMR spectroscopy grants insights into molecular motions, interactions and chemical transitions at atomic-level resolution. However, it faces challenges when observing small-molecule ligands within large complexes: The first prerequisite are NMR active nuclei. Unlike biomolecular NMR, where isotope labelling is routine, the site-directed introduction of desired nuclei into small molecules still requires lengthy, individual synthesis.
Second, transverse-relaxation optimised experiments have been instrumental in pushing the size limits of protein-observed NMR into the biologically relevant range of tens to hundreds of kilodaltons. Such experiments are not directly transferable to the small molecule space due to its different chemical build-up. ZoomNMR proposes to cover this blind spot with a spectroscopic toolbox for ligand-detected NMR of large macromolecular complexes.
Our approach capitalizes on late-stage isotope labelling strategies, inspired by organic chemistry, in conjunction with relaxation interference phenomena to maximize sensitivity and resolution. The tools will be implemented on a prototypical human enzyme and three exemplary ligand classes. We will deliver a proof-of-concept that our novel methodology can tackle diverse research problems, from fundamental mechanistic enzymology to the design of drug molecules.
Our future vision is that ligand-observed NMR of large complexes will become as straightforward and efficient as protein-observed NMR is today.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Ludwig-Maximilians-Universitaet Muenchen | Planegg | Germany | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI